Literature DB >> 21169110

[Prevalence and clinical characteristics of the IBS subtypes according to the Rome III criteria in patients from a clinical, multicentric trial. A report from the Mexican IBS Working Group].

M Schmulson1, J A Vargas, A López-Colombo, J M Remes-Troche, J C López-Alvarenga.   

Abstract

BACKGROUND: In Mexico the prevalence of irritable bowel síndrome (IBS) using Rome II criteria varies between 16 and 35%.
OBJECTIVE: To analyze the relative frequency of the IBS subtypes according to the Rome III criteria.
METHODS: A multicentric study in 1677 IBS-Rome III patients that consulted private medical clinics. They all answered a structured interview by their physicians to determine the IBS subtype and to evaluate their symptoms intensity (Likert Scales). Patients self-evaluated their symptoms as well by using 10 cm visual analog scales for each one.
RESULTS: Women represented 76.8% of the patients for a F:M ratio of 3.3:1. The relative frequencies of the IBS subtypes were IBS-M: 48.4%, IBS-E: 43.0%, IBS-D: 5.6% and IBS-U: 2.8% with females predominating among all. However, IBS-D included 1.7 to 2.4 times more men than any of the other subtypes. The IBS-M reported a higher frequency and intensity of halitosis and vomiting and a higher intensity of burping; while those with IBS-E reported a higher frequency and intensity of straining and the IBS-D more urgency for a bowel movement, fecal incontinence and mucous in the stools.
CONCLUSIONS: In IBS-Rome III patients in Mexico, IBS-M is the most common subtype and is more commonly associated with dyspeptic symptoms while the IBS-E reported more outlet symptoms and the IBS-D fecal incontinence. There is a higher female predominance amongst all, however men are more likely to be in IBS-D.

Entities:  

Mesh:

Year:  2010        PMID: 21169110

Source DB:  PubMed          Journal:  Rev Gastroenterol Mex        ISSN: 0375-0906


  5 in total

1.  Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern.

Authors:  A M Su; W Shih; A P Presson; L Chang
Journal:  Neurogastroenterol Motil       Date:  2013-08-29       Impact factor: 3.598

2.  Blastocystis infection is associated with irritable bowel syndrome in a Mexican patient population.

Authors:  Diego Emiliano Jimenez-Gonzalez; Williams Arony Martinez-Flores; Jesus Reyes-Gordillo; Maria Elena Ramirez-Miranda; Sara Arroyo-Escalante; Mirza Romero-Valdovinos; Damien Stark; Valeria Souza-Saldivar; Fernando Martinez-Hernandez; Ana Flisser; Angelica Olivo-Diaz; Pablo Maravilla
Journal:  Parasitol Res       Date:  2011-08-26       Impact factor: 2.289

3.  Assessment of Anti-vinculin and Anti-cytolethal Distending Toxin B Antibodies in Subtypes of Irritable Bowel Syndrome.

Authors:  Ali Rezaie; Sung Chul Park; Walter Morales; Emily Marsh; Anthony Lembo; Jae Hak Kim; Stacy Weitsman; Kathleen S Chua; Gillian M Barlow; Mark Pimentel
Journal:  Dig Dis Sci       Date:  2017-04-27       Impact factor: 3.199

4.  The epidemiology of functional gastrointestinal disorders in Mexico: a population-based study.

Authors:  Aurelio López-Colombo; Douglas Morgan; Dalia Bravo-González; Alvaro Montiel-Jarquín; Socorro Méndez-Martínez; Max Schmulson
Journal:  Gastroenterol Res Pract       Date:  2012-03-19       Impact factor: 2.260

5.  Efficacy of the Combination of Pinaverium Bromide 100 mg Plus Simethicone 300 mg in Abdominal Pain and Bloating in Irritable Bowel Syndrome: A Randomized, Placebo-controlled Trial.

Authors:  Max J Schmulson; Jazmin Chiu-Ugalde; Adolfo Sáez-Ríos; Aurelio López-Colombo; Gualberto J Mateos-Pérez; José María Remes-Troche; Sergio Sobrino-Cossio; Julio C Soto-Pérez; José L Tamayo de la Cuesta; Oscar T Teramoto-Matsubara; Juan C López-Alvarenga
Journal:  J Clin Gastroenterol       Date:  2020-04       Impact factor: 3.174

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.